Brief: Jacobio Gets CDE Approval For Glecirasib's Pancreatic Cancer Pivotal Study In China
04/07/2023 14:19
July 4 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* JACOBIO RECEIVES CDE APPROVAL FOR GLECIRASIB'S PANCREATIC
CANCER
PIVOTAL STUDY IN CHINA
Source text for Eikon: ID:nPn2GS4pha
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan